Tesamorelin vs CJC-1295

What are tesamorelin and CJC-1295?

Both are synthetic growth-hormone-releasing hormone (GHRH) analogs that prompt the pituitary gland to secrete natural growth hormone.

GHRH is the upstream signal your body normally uses to trigger pulses of growth hormone. A GHRH analog copies that signal, so the resulting growth hormone and downstream IGF-1 rise follow the body's own pulsatile pattern rather than a flat external dose. Tesamorelin and CJC-1295 both fall in this class, but they were developed for different purposes and carry very different amounts of published human evidence.

Tesamorelin was studied and approved for a specific clinical outcome: reduction of excess visceral (deep abdominal) fat. In the trial reported by Falutz et al., 2007, tesamorelin reduced visceral adipose tissue by about 15.2 percent compared with placebo over the study period.

CJC-1295 was studied mainly for its pharmacology, meaning how long and how strongly it raises growth hormone and IGF-1. Teichman et al., 2006 reported that CJC-1295 produced sustained elevations of both hormones across multiple days after dosing.

Which one is FDA-approved?

Tesamorelin has a completed regulatory pathway for a named indication; CJC-1295 remains a research compound.

Tesamorelin's approval traces to the visceral-fat outcome documented by Falutz et al., 2007, published in the New England Journal of Medicine. That is a controlled trial with a defined primary endpoint measured by imaging.

CJC-1295, by contrast, is supported chiefly by early-phase human pharmacology (Teichman et al., 2006). That study established that the peptide raises growth hormone and IGF-1 and that the effect persists over days, but it is not the same as a large outcome trial on a disease endpoint. For a searcher weighing the two, this is the sharpest single difference: one has a completed indication, the other has early signal data.

How do their effects on IGF-1 compare?

Both raise IGF-1, but the published data describe different things: tesamorelin's data centers on a fat outcome, CJC-1295's on the duration of hormone elevation.

Teichman et al., 2006 specifically reported that CJC-1295 sustained growth hormone and IGF-1 levels over an extended window after a single administration, which is the feature that made it interesting as a research peptide. Falutz et al., 2007 reported growth hormone axis activity alongside the primary visceral-fat reduction, but the headline finding there was the roughly 15.2 percent drop in visceral adipose tissue.

For broader context on this peptide class, other GHRH-axis and secretagogue agents have shown their own IGF-1 effects. CJC-1295 in the Teichman work, and separately ipamorelin as a selective growth hormone secretagogue (Raun et al., 1998), illustrate how different molecules in this neighborhood target the same axis by different routes.

Comparison table: tesamorelin vs CJC-1295

Direct side-by-side, drawn only from the named studies.

What does the research report about dosing?

Research-reported ranges are shown below for reference only; this is not a recommendation, and any personal dose belongs with a qualified clinician.

The values below come directly from the two named trials and describe what participants received in those studies, not what any reader should take.

We do not publish an injection schedule, a stacking plan, or a cycling plan. Those decisions require individual medical evaluation.

What are the differences in side-effect profile?

The two carry different evidence bases for safety, which matters more than any head-to-head claim.

Because tesamorelin has a completed trial pathway (Falutz et al., 2007), its adverse-event data was collected in a controlled setting with a comparison group. CJC-1295's safety picture rests on the smaller early-phase work (Teichman et al., 2006), so the human safety dataset is narrower.

More broadly, agents that push the growth hormone axis can affect glucose handling. That is documented for the oral secretagogue MK-677, where Nass et al., 2008 reported raised fasting glucose and reduced insulin sensitivity. MK-677 is a different molecule, but it is a useful reminder that growth-hormone-axis compounds are not metabolically neutral and warrant clinical oversight.

Which one should a researcher consider?

The honest answer depends on the question being asked, and the evidence points in two different directions.

If the interest is a defined, imaging-measured outcome backed by a controlled trial, tesamorelin is the one with that record (Falutz et al., 2007). If the interest is the pharmacology of sustained growth hormone and IGF-1 elevation, CJC-1295 is the molecule that early human data describes (Teichman et al., 2006). Neither of these is a treatment recommendation. The class as a whole acts on the growth hormone axis, and that axis interacts with metabolism, so a qualified clinician should guide any individual decision.